Synopsis
0
EU WC
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Epilincomycin
2. Hemihydrate Lincomycin Monohydrochloride
3. Lincocin
4. Lincolnensin
5. Lincomycin
6. Lincomycin A
7. Lincomycin Monohydrochloride
8. Lincomycin Monohydrochloride, (2s-cis)-isomer
9. Lincomycin Monohydrochloride, (l-threo)-isomer
10. Lincomycin Monohydrochloride, Hemihydrate
11. Lincomycin, (2s-cis)-isomer
12. Lincomycin, (l-threo)-isomer
1. 859-18-7
2. Lincomycin Hcl
3. Frademicina
4. Lincomycin (hydrochloride)
5. Mycivin
6. Lincomycin Hydrochloride Anhydrous
7. Nsc 70731
8. Lincocin
9. Gcw8y9936l
10. Lincomix 20
11. Pura Ject 100
12. Ncgc00159326-02
13. Lincolnensin, Hydrochloride
14. Dsstox_cid_27780
15. Dsstox_rid_82556
16. Dsstox_gsid_47803
17. (2s,4r)-n-((1r,2r)-2-hydroxy-1-((2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)propyl)-1-methyl-4-propylpyrrolidine-2-carboxamide Hydrochloride
18. Lincolnensin Hydrochloride
19. Antibiotic 124a, Hydrochloride
20. Lincogap
21. U 10149a
22. Lincocin Hydrochloride
23. Unii-gcw8y9936l
24. Mfcd00083647
25. Einecs 212-726-7
26. Cas-859-18-7
27. Lincomycin Hcl (lincocin)
28. Ec 212-726-7
29. Schembl192964
30. Chembl1201097
31. Dtxsid7047803
32. Hy-b0417a
33. Lincocin Hydrochloride Monohydrate
34. Tox21_111575
35. Akos024375415
36. Tox21_111575_1
37. Ccg-220302
38. Anhydrous Lincomycin Hydrochloride
39. Lincomycin Hydrochloride [who-dd]
40. Ncgc00159326-03
41. As-13720
42. Lincomycin Hydrochloride, >=90% (tlc)
43. Lincomycin Hydrochloride, >=95.0% (tlc)
44. L0166
45. Lincomycin Hydrochloride Anhdrous [mi]
46. Lincomycin Hydrochloride For System Suitability
47. 859l187
48. A841491
49. Anhydrous Lincomycin Hydrochloride [mart.]
50. Q27279041
51. Lincomycin Hydrochloride, Bioreagent, Suitable For Cell Culture
52. Lincomycin Hydrochloride, British Pharmacopoeia (bp) Reference Standard
53. (2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylsulfanyl)oxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboximidic Acid Hydrochloride
54. (2s-trans)-methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-d-erythro-.alpha.-d-galacto-octopyranoside Hydrochloride
55. D-erythro-.alpha.-d-galacto-octopyranoside, Methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, Monohydrochloride, (2s-trans)-
56. D-erythro-.alpha.-d-galacto-octopyranoside, Methyl 6,8-dideoxy-6-[[[(2s,4r)-1-methyl-4-propyl-2-pyrrolidinyl]carbonyl]amino]-1-thio-, Hydrochloride (1:1)
57. D-erythro-alpha-d-galacto-octopyranoside, Methyl 6,8-dideoxy-6-((((2s,4r)-1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, Monohydrochloride
58. D-erythro-alpha-d-galacto-octopyranoside, Methyl 6,8-dideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, Monohydrochloride, (2s-trans)-
59. D-erythro-d-galacto-octopyranoside, Methyl 6,8-dideoxy-6-(1-methyl-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-, Monohydrochloride, Trans-alpha-
60. Hydron; N-[2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl)propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide; Chloride;(2s,4r)-n-{(1s)-2-hydroxy-1-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(methylthio)-tetrahydro-2h-2-pyranyl]propyl}-1-methyl-4-propylpyrrolidine-2-carboxamide Hydrochloride
61. Methyl (2s-trans)-6,8-dideoxy-6-(((1-methyl-4-propylpyrrolidin-2-yl)carbonyl)amino)-1-thio-d-erythro-alpha-d-galacto-octopyranoside Monohydrochloride
62. Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-l-2-pyrrolidinecarboxamido)-1-thio-d-erythro-.alpha.-d-galacto-octopyranoside Monohydrochloride
| Molecular Weight | 443.0 g/mol |
|---|---|
| Molecular Formula | C18H35ClN2O6S |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 442.1904357 g/mol |
| Monoisotopic Mass | 442.1904357 g/mol |
| Topological Polar Surface Area | 148 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 499 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Lincocin |
| PubMed Health | Lincomycin (Oral route, Injection route) |
| Drug Classes | Antibiotic, Lincosamide |
| Drug Label | LINCOCIN Sterile Solution contains lincomycin hydrochloride which is the monohydrated salt of lincomycin, a substance produced by the growth of a member of the lincolnensis group of Streptomyces lincolnensis (Fam. Streptomycetaceae). The chemical nam... |
| Active Ingredient | Lincomycin hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 300mg base/ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 2 | |
|---|---|
| Drug Name | Lincocin |
| PubMed Health | Lincomycin (Oral route, Injection route) |
| Drug Classes | Antibiotic, Lincosamide |
| Drug Label | LINCOCIN Sterile Solution contains lincomycin hydrochloride which is the monohydrated salt of lincomycin, a substance produced by the growth of a member of the lincolnensis group of Streptomyces lincolnensis (Fam. Streptomycetaceae). The chemical nam... |
| Active Ingredient | Lincomycin hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 300mg base/ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Parenteral
Solubilizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
94
PharmaCompass offers a list of Lincomycin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lincomycin Hydrochloride manufacturer or Lincomycin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lincomycin Hydrochloride manufacturer or Lincomycin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Lincomycin Hydrochloride API Price utilized in the formulation of products. Lincomycin Hydrochloride API Price is not always fixed or binding as the Lincomycin Hydrochloride Price is obtained through a variety of data sources. The Lincomycin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A H021 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of H021, including repackagers and relabelers. The FDA regulates H021 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. H021 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of H021 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A H021 supplier is an individual or a company that provides H021 active pharmaceutical ingredient (API) or H021 finished formulations upon request. The H021 suppliers may include H021 API manufacturers, exporters, distributors and traders.
click here to find a list of H021 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A H021 DMF (Drug Master File) is a document detailing the whole manufacturing process of H021 active pharmaceutical ingredient (API) in detail. Different forms of H021 DMFs exist exist since differing nations have different regulations, such as H021 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A H021 DMF submitted to regulatory agencies in the US is known as a USDMF. H021 USDMF includes data on H021's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The H021 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of H021 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The H021 Drug Master File in Japan (H021 JDMF) empowers H021 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the H021 JDMF during the approval evaluation for pharmaceutical products. At the time of H021 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of H021 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a H021 Drug Master File in Korea (H021 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of H021. The MFDS reviews the H021 KDMF as part of the drug registration process and uses the information provided in the H021 KDMF to evaluate the safety and efficacy of the drug.
After submitting a H021 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their H021 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of H021 suppliers with KDMF on PharmaCompass.
A H021 CEP of the European Pharmacopoeia monograph is often referred to as a H021 Certificate of Suitability (COS). The purpose of a H021 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of H021 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of H021 to their clients by showing that a H021 CEP has been issued for it. The manufacturer submits a H021 CEP (COS) as part of the market authorization procedure, and it takes on the role of a H021 CEP holder for the record. Additionally, the data presented in the H021 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the H021 DMF.
A H021 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. H021 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of H021 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing H021 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for H021 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture H021 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain H021 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a H021 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of H021 suppliers with NDC on PharmaCompass.
H021 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of H021 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right H021 GMP manufacturer or H021 GMP API supplier for your needs.
A H021 CoA (Certificate of Analysis) is a formal document that attests to H021's compliance with H021 specifications and serves as a tool for batch-level quality control.
H021 CoA mostly includes findings from lab analyses of a specific batch. For each H021 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
H021 may be tested according to a variety of international standards, such as European Pharmacopoeia (H021 EP), H021 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (H021 USP).
